Market Report, "Switzerland Pharmaceuticals & Healthcare Report Q4 2010", published

New Healthcare research report from Business Monitor International is now available from Fast Market Research
 
Sept. 21, 2010 - PRLog -- In BMI's Q410 Pharmaceuticals & Healthcare Business Environment Ratings (BERs), the Western Europe region scored a total of 64.5 out of a 100. The attractiveness of the region to pharmaceutical firms stems from the fact that its countries are key revenue sources for 'big pharma', particularly for companies selling high-end products, as per-capita spending is substantially higher than in emerging markets.

However, it is BMI's view that drug companies will face many challenges in Western Europe over the next decade, including the need to reduce fiscal deficits, the patent cliff, added regulatory hurdles and increasingly scrupulous cost-effectiveness assessments of new drugs - all factors that will influence the risk and reward scores assigned to markets in the region. Deficits remain a key challenge for the majority of governments across Europe. New fiscal austerity measures in the eurozone in an attempt to calm bond markets have reinforced our weak growth outlook, adding to existing problems of over-leverage.

With regards to Switzerland, in 2009, price cuts led to savings of approximately CHF400mn (US$361mn), while those implemented at the start of 2010 are aimed at creating savings of approximately CHF800mn (US$721mn). They include changes in wholesale margins, reference pricing and realigning the prices of generic medicines. We therefore forecast the country's drug market will decline in value in 2010, falling from CHF6.07bn (US$5.58bn) in 2009 to CHF5.95bn (US$5.60bn), equating to negative growth of 2.00% in local currency terms and marginally positive growth of 0.37% in US dollar terms.

Furthermore, despite a CAGR of 2.82% in local currency terms and 5.62% in US dollar terms from 2004- 2009, BMI's outlook for the Swiss drug market is less optimistic over the next five years. From 2009- 2014, a CAGR of -0.85% is projected in local currency terms (-3.29% in US dollar terms), largely as a result of the impending patent cliff and the consequent consumption of lower-value generic drugs in place of high-value patented drugs, in addition to the price cuts enforced in 2010. By 2014, pharmaceutical expenditure in Switzerland is expected to reach a value of CHF5.69bn (US$4.63bn).

Highlighting the effect of government austerity measures, Swiss company Novartis's Q210 sales indicate that the company's sales in Europe have suffered. The company's net sales grew by 11% to US$11.7bn in Q210 (compared with Q209) resulting in an 18% increase in H110 net sales to US$23.8bn, up from US$20.2bn H109. Additionally, net income increased by 16% to US$2.7bn in Q210 (compared with Q209), resulting in a 29% increase in H110 net income to US$6.08bn - a marked increase from US$4.70bn in H109.

However, Novartis's financial performance in Q210, when compared to Q110, indicates that the company has suffered. Net sales fell by 3% from US$12.1bn in Q110 to US$11.7bn in Q210 and net income fell 17% from US$2.9bn to 2.4bn.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/83364_switzerland_pharmaceutic...

Partial Table of Contents:

CONTENTS
Executive Summary
SWOT Analysis
- Switzerland Pharmaceuticals And Healthcare Industry SWOT
- Switzerland Political SWOT
- Switzerland Economic SWOT
Pharmaceutical Business Environment Ratings
- Table: Western Europe - Regional Pharmaceutical Business Environment Ratings for Q410
- Rewards
- Risks
Switzerland - Market Summary
Regulatory Regime
- Recent Regulatory Developments
- Intellectual Property Regime
- Counterfeit Medicines
- Pricing Regime
- Recent Pricing System Developments
- Reimbursement Regime
Industry Developments
- Epidemiology
- Non-Communicable Disease
- Communicable Disease
- Health Insurance
- Healthcare Sector Financing
- Pharmaceutical Wholesale and Retail Sector
- Research And Development Sector
- Biotechnology Sector
- Clinical Trials
Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: Switzerland - Economic Activity
- Prescription Drug Market Forecast
- Patented Drug Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Medical Device Market Forecast
- Pharmaceutical Trade Forecast
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Recent Company Developments
Company Monitor
- Indigenous Manufacturers
- Novartis
- Roche
- Merck-Serono
- Leading Multinational Manufacturers
- GlaxoSmithKline (GSK)
- Pfizer
- Sanofi-Aventis
- Merck & Co
Country Snapshot: Switzerland Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Wages, 2000-2012
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceuticals Business Environment Ratings
- Risk/Reward Ratings Methodology
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=8336...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
End
Source: » Follow
Email:***@fastmr.com Email Verified
Zip:01267
Tags:Pharmaceutical, Drug, Ratings, Healthcare, Q210, Regime, Novartis, Regulatory, Dollar, Currency
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share